May 2nd 2024
Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Microvascular function is lower in Black men after prostate cancer diagnosis
April 8th 2024“Given that non-Hispanic Black men were 4 years younger than the non-Hispanic White men, these data suggest that microvascular dysfunction may appear earlier in non-Hispanic Black men following a prostate cancer diagnosis," says Abigayle B. Simon.
The management of high-risk localized prostate cancer: Back to the future
April 5th 2024"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.
Dr. Patel and Dr. Aworunse discuss prostate cancer among US veterans
April 2nd 2024"We hope that this paper encourages urologists to rethink non definitive treatment/active surveillance for prostate cancer and consider definitive treatment options earlier in the treatment pathway based on evidence that has accumulated," says Mital Patel, MD.
Dr. Vickers on quantifying Gleason pattern 4 in prostate cancer
March 30th 2024“I would just say that urologists should be focusing much more on the total amount of pattern 4, if they have that information available, than on the ratio of pattern 3 and 4, and therefore the grade group,” says Andrew J. Vickers, PhD.
Targeted radiation plus systemic therapy combo shows promise in mHSPC
March 18th 2024"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.
Relugolix now available in Canada for advanced prostate cancer
March 13th 2024"Now, physicians in Canada have a once-daily oral GnRH antagonist treatment option in their armamentarium that helps men with advanced prostate cancer by lowering testosterone levels without leading to testosterone flares,” said Fred Saad, MD, FRCS.